Open AccessHucMSC-Ex alleviates inflammatory bowel disease via the lnc78583-mediated miR3202/HOXB13 pathway
Author(s) -
Yuting Xu,
Li Zhang,
Dickson Kofi Wiredu Ocansey,
Bo Wang,
Yilin Hou,
Rong Mei,
Yongsheng Yan,
Xu Zhang,
Zhaoyang Zhang,
Fei Mao
Publication year - 2022
Publication title -
journal of zhejiang university. science b
Language(s) - English
Resource type - Journals
eISSN - 1862-1783
pISSN - 1673-1581
DOI - 10.1631/jzus.b2100793
Subject(s) - ulcerative colitis , medicine , inflammatory bowel disease , diarrhea , disease , incidence (geometry) , rectum , gastroenterology , inflammation , distal colon , immune system , abdominal pain , colitis , immunology , physics , optics
As a group of nonspecific inflammatory diseases affecting the intestine, inflammatory bowel disease (IBD) exhibits the characteristics of chronic recurring inflammation, and was proven to be increasing in incidence (Kaplan, 2015). IBD induced by genetic background, environmental changes, immune functions, microbial composition, and toxin exposures (Sasson et al., 2021) primarily includes ulcerative colitis (UC) and Crohn's disease (CD) with complicated clinical symptoms featured by abdominal pain, diarrhea, and even blood in stools (Fan et al., 2021; Huang et al., 2021). UC is mainly limited to the rectum and the colon, while CD usually impacts the terminal ileum and colon in a discontinuous manner (Ordás et al., 2012; Panés and Rimola, 2017). In recent years, many studies have suggested the lack of effective measures in the diagnosis and treatment of IBD, prompting an urgent need for new strategies to understand the mechanisms of and offer promising therapies for IBD.